Cantor Fitzgerald Issues Negative Forecast for BCRX Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Investment analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of BioCryst Pharmaceuticals in a research report issued on Wednesday, October 15th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the biotechnology company will post earnings per share of $0.05 for the year, down from their previous estimate of $0.06. Cantor Fitzgerald has a “Overweight” rating and a $26.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share.

BCRX has been the topic of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 8th. Evercore ISI reissued an “in-line” rating and issued a $8.00 price target on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Zacks Research raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Bank of America increased their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, July 1st. Finally, Wedbush increased their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an “outperform” rating in a report on Monday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.18.

BioCryst Pharmaceuticals Stock Down 1.3%

BioCryst Pharmaceuticals stock opened at $6.72 on Thursday. The stock has a market cap of $1.41 billion, a P/E ratio of -37.33, a P/E/G ratio of 1.43 and a beta of 1.05. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.31. The company’s 50-day moving average price is $7.87 and its two-hundred day moving average price is $8.64.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. The company’s revenue for the quarter was up 49.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.06) earnings per share.

Insider Activity at BioCryst Pharmaceuticals

In other news, Director Theresa Heggie sold 70,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director directly owned 65,352 shares of the company’s stock, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in BCRX. GAMMA Investing LLC increased its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 5,449 shares during the period. SG Americas Securities LLC increased its stake in BioCryst Pharmaceuticals by 5.2% in the first quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company’s stock valued at $326,000 after acquiring an additional 2,146 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in BioCryst Pharmaceuticals by 113.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 37,671 shares of the biotechnology company’s stock valued at $283,000 after acquiring an additional 20,043 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in BioCryst Pharmaceuticals in the first quarter valued at approximately $79,000. Finally, Cerity Partners LLC increased its stake in BioCryst Pharmaceuticals by 203.6% in the first quarter. Cerity Partners LLC now owns 36,410 shares of the biotechnology company’s stock valued at $273,000 after acquiring an additional 24,418 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.